Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03539757 · ClinicalTrials.gov registry record

Development of Novel MRI Methods for Detecting, Discriminating, and Measuring Liver Fibrosis and Congestion in Fontan Patients

A clinical trial, sponsored by Children's Hospital Medical Center, Cincinnati.

Terminated
Registry status
6
Enrollment target

NCT03539757: Clinical Trial study, sponsored by Children's Hospital Medical Center, Cincinnati.

NCT03539757 is a clinical trial that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03539757 was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.

TERMINATED
Registry status
6 participants
Enrollment target

Study Summary

In this research study, the investigators will conduct a prospective cross-sectional study of pediatric and adult Fontan patients that will correlate a variety of quantitative MRI biomarkers with histopathologic data.

Primary Outcome

MR elastography of the liver data will be correlated with histopathologic data obtained from non-lesional liver tissue. Histologic fibrosis and congestion will be scored by a pathologist using semi-quantitative grading systems (e.g., METAVIR scoring system for fibrosis

Interventions

  • DEVICE Non-Contrast Magnetic Resonance Imaging

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2018-05-09
Est. Completion 2022-03-30

Why NCT03539757 stopped before completion

NCT03539757 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Non-Contrast Magnetic Resonance Imaging is the first listed.

NCT03539757 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03539757 about?

NCT03539757 is a clinical study titled "Development of Novel MRI Methods for Detecting, Discriminating, and Measuring Liver Fibrosis and Congestion in Fontan Patients". In this research study, the investigators will conduct a prospective cross-sectional study of pediatric and adult Fontan patients that will correlate a variety of quantitative MRI biomarkers with histopathologic data.

What is the current status of trial NCT03539757?

This trial is currently terminated. The enrollment target is 6 participants. The study started on 2018-05-09. Estimated completion is 2022-03-30.

What interventions are being tested in trial NCT03539757?

The interventions under investigation include: Non-Contrast Magnetic Resonance Imaging (DEVICE).

Who is sponsoring clinical trial NCT03539757?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03539757, the US trial registry maintained by the National Library of Medicine. NCT03539757 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.